摘要
目的探讨SMRP、HE4和CA125检测对卵巢癌的诊断价值。方法整群收集2010年1月—2013年12月该院收治的58例卵巢癌患者、60例良性卵巢病变患者及60例正常体检者分为3组,进行SMRP、HE4、CA125检测。结果SMRP在卵巢癌组的表达明显高于其他两组(P<0.05);HE4在卵巢癌组中的表达明显高于其他两组(P>0.05);CA125在正常对照组的表达较低,卵巢癌组的表达高于正常对照组和良性病变组(P<0.05),卵巢良性病变组的表达也高于正常对照组,但差异无统计学意义(P>0.05)。结论 HE4、SMRP、CA125对卵巢癌有较好的检测价值。
Objective To explore the SMRP, HE4 and CA125 testing value to the diagnosis of ovarian cancer. Methods Collected from January 2010 to December 2013, our hospital of 58 patients with ovarian cancer, 60 patients with benign ovarian lesions and 60 cases of normal physical examination is divided into three groups, to SMRP, HE4 and CA125 detection.Results SMRP expression in observation group was obviously higher than that of other two groups(P<0.05); HE4 expression in ovarian cancer group is significantly higher than the other two groups(P>0.05); Lower the expression of CA125 in the normal control group, the expression of ovarian cancer group was higher than normal control group and benign lesion group(P<0.05), the expression of ovarian benign lesions group is higher than that of normal control group, but no significant difference,no statistical significance(P>0.05). Conclusion HE4, SMRP and CA125 in ovarian cancer have better detection value.
出处
《中外医疗》
2015年第31期172-173,175,共3页
China & Foreign Medical Treatment
